SynthesisCancer reports (Hoboken, N.J.)2025
The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX-351) in Acute Myeloid Leukemia Patients: A Systematic Review.
Synthesis in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Nanoparticle-Based Drug Delivery Systems: Current Advances and Future Directions.Current drug targets · 2026Review
- Unraveling Research Trends and Hotspots of Genetic Variants in Acute Leukemias: A Web of Science and Scopus-Based Bibliometric Study.International journal of medical sciences · 2026Article
- Nanotechnology for the Efficacious Delivery of Medicinal Cannabis and Pharmaceutical Medicines.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) is an aggressive blood cancer with a poor prognosis when treated using conventional chemotherapy. CPX-351, a liposomal formulation of cytarabine and daunorubicin, has demonstrated potential as a novel therapeutic strategy.
aimThis systematic review aims to evaluate the clinical safety and efficacy of CPX-351 compared to standard induction chemotherapy in patients with AML.
methodsA systematic literature search was conducted using Web of Science, PubMed, Google Scholar, Ovid MEDLINE, and the Cochrane Library from 2011 to 2023. Overall, 14 clinical trials with more than 800 AML patients were included. Data on adverse events, survival outcomes, and response rates were extracted and analyzed.
resultsCPX-351 exhibited an adverse event profile that was comparable to that of conventional chemotherapy. It resulted in complete remission rates of 18%-41% in relapsed/refractory AML patients. For newly diagnosed individuals, CPX-351 led to complete remission rates of 41%-58%, surpassing the 14%-40% associated with standard chemotherapy. Additionally, it extended overall survival by 3.6-5.7 months, with significant advantages noted in high-risk cytogenetics and secondary AML cases.
conclusionThis review presents strong evidence supporting CPX-351 as a therapeutic alternative with superior efficacy and comparable safety to standard chemotherapy across diverse AML populations. This represents a breakthrough in therapy, with demonstrated efficacy in AML cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.